Cerebroside sulfatase

2024年2月1日，武田制药宣布其首席财务官Costa Saroukos离职，并且公司削减一系列管道。武田表示Saroukos将于2024年4月1日卸任首席财务官一职，并将继续担任公司董事直至2024年6月28日。武田制药日本制药业务部门总裁Milano Furuta将接替Saroukos担任首席财务官。辞职原因是Saroukos决定回到老家澳大利亚，离家人更近。Saroukos个人生涯Saroukos于2015年加入武田，担任欧洲和加拿大部门的首席财务官，2018年4月被任命为武田全球首席财务官。在武田向全球生物制药公司的转型过程中Saroukos发挥了关键作用。他在武田收购和整合 Shire PLC.（日本公司有史以来最大的海外收购）期间发挥的领导作用是交易成功的关键因素，他的财务管理帮助公司重新专注于增长投资和股东回报。Saroukos拥有宾夕法尼亚大学沃顿商学院工商管理硕士学位和日本一桥大学国际事务学士学位。2000年他在日本开始了他的职业生涯，从事银行和私募股权投资，在那里他参与了多种类型的金融交易，包括杠杆收购和债务重组。在加入武田之前，他曾在美国一家投资管理公司担任股票研究分析师。在成为JPBU总裁之前，Saroukos曾担任武田的企业战略官和办公室主任，并在该公司的全球范围内担任过多个领导职务。产品版图扩展顺利同一时间，武田公布了2023财年第三季度（截止2023年12月31日止）的财报，第三季度业绩增长势头强劲并且有多款新产品获批上市。财年的前九个月，武田全球总收入为3.21万亿日元（约合220亿美元），按固定汇率计算，这一数字与上一年持平。由于专利到期，其药物Vyvanse的销售额下降了12.1%，至3129亿日元（21.4亿美元）。2023年11月8日，和黄医药与武田共同开发的Fruzaqla（呋喹替尼/fruquintinib）被FDA批准，用于治疗既往曾接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗、抗血管内皮生长因子治疗，以及抗表皮生长因子受体(EGFR)治疗(若属RAS野生型及医学上适用)的成人转移性结直肠癌患者。2023年11月9日，FDA批准武田的Adzynma用于先天性血栓性血小板减少性紫癜（cTTP）成人和儿童患者的预防性或按需酶替代疗法（ERT）。财报期内，ENTYVIO ®（vedolizumab）的皮下 (SC) 给药制剂在美国上市，该药在2023年9月被FDA批准用于成人中度至重度活动性溃疡性结肠炎（UC）接受ENTYVIO静脉注射（IV）诱导治疗后的维持治疗。武田表示，近几个月来，Entyvio保持了其在美国IBD市场的领先地位，在公司本财年的前九个月，全球销售额增长了7%。2023年12月21日，其抗病毒感染药物马利巴韦片（Livtencity）获得NMPA批准，用于治疗造血干细胞移植或实体器官移植后巨细胞病毒(CMV)感染和/或疾病，且对一种或多种既往治疗（更昔洛韦、缬更昔洛韦、西多福韦或膦甲酸钠）难治（伴或不伴基因型耐药）的成人患者。砍掉的管线2023年武田上半年总销售约138.71亿美元，同比增长1.4%，但利润却大幅下滑，下降了53%，约为17.87亿美元。由于一系列不可控因素，导致了公司的净亏损增长，武田将全年净利润预测下调了高达71%，并且砍掉4条管线。Exkivity：治疗肺癌产品Exkivity的一项一线治疗晚期非小细胞肺癌的III期临床试验（EXCLAIM-2）因为无疗效获益而终止。武田经与FDA商议后决定将在美国启动Exkivity的主动退市。TAK-920/DNL-919：武田及其合作伙伴Denali在最高剂量下出现"中度、可逆的血液学效应"后，停止了阿尔茨海默氏症（AD）候选药物DNL-919（ATV：TREM2）的开发。TAK-611：候选药物酶替代疗法TAK-611在治疗异染性脑白质营养不良（MLD）的II期试验中未达到主要终点和次要终点。TAK-105：由于数据不支持进一步开发，治疗恶心和呕吐的候选药物 TAK-105将从第一阶段开发中撤出。此前，武田还终止了12个研发项目以及放弃了AAV基因治疗管线。而第三季度的财报显示净亏损应然是增长的。该公司在财报中表示，在短期内，即2024财年至2025财年，武田的目标是恢复销售、利润和利润率的增长。参考来源：1.https://endpts.com/takeda-says-farewell-to-cfo-suite-of-clinical-stage-programs-in-q3-update/2.https://www.takeda.com/newsroom/newsreleases/2024/takeda-announces-chief-financial-officer-succession/3.https://weibo.com/ttarticle/p/show?id=2309404970443319673484本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处········

Takeda’s pipeline cull affected assets outside of oncology. Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday when the drugmaker axed (PDF) a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline. Under CEO Christophe Weber, Takeda has worked to establish itself as a leader in oncology. But, as the executive said on a quarterly results call with investors, the company has “had some wins ... [and] some setbacks.” The results brought news of more setbacks, with Takeda using the update to reveal it has dropped a clutch of cancer candidates led by modakafusp alfa. Formerly known as TAK-573, modakafusp alfa consists of two interferon alpha-2b molecules fused to an anti-CD38 monoclonal antibody. The idea was to activate innate and adaptive immune cells—while also directly stopping the proliferation of multiple myeloma cells—through targeted interferon signaling. Takeda began a phase 1/2a Darzalex combination trial one year ago, adding to the slate of studies run in support of the immunocytokine, but has now pulled the plug on the program. Andrew Plump, M.D., Ph.D., president of R&D at Takeda, explained the decision on the conference call with investors.  “This is a strategic decision based on a number of factors, including the existing data set, the rapidly evolving multiple myeloma treatment landscape and the long development timelines,” the R&D chief said.  Takeda pushed modakafusp alfa out of the door as part of a pipeline clear-out that also hit three phase 1 autologous CAR-T candidates. Two of the prospects, GPC3-targeted TAK-102 and mesothelin-directed TAK-103, were in development in solid tumors. The third asset, TAK-940, was a CD19-directed, Memorial Sloan Kettering Cancer Center-partnered program that used the 1XX domain to try to enhance efficacy. While Takeda axed a clutch of cancer candidates, Plump said the company “remains committed to oncology and will continue to develop therapies across hematologic and solid tumors.” The R&D chief highlighted the SUMO inhibitor subasumstat, a pair of STING agonists and two T-cell engagers from the Maverick Therapeutics acquisition as candidates to watch.  Plump also cited the appointment of PK Morrow, who joined Takeda from CRISPR Therapeutics last month, as a boost for the oncology unit. Morrow became head of the oncology therapeutic area unit at Takeda, having previously worked as chief medical officer of CRISPR, and held various roles at Amgen. Takeda’s pipeline cull also affected assets outside of oncology. The drugmaker removed three phase 2 drug candidates, namely the rare disease asset TAK-611—which flunked a trial last year—the Parkinson’s disease prospect TAK-071 and the depression molecule TAK-041. In phase 1, Takeda axed treatments for Alzheimer’s disease and nausea as well as a Zika vaccine candidate. Amid the changes, Takeda grew its R&D spend by 7.3%, although Chief Financial Officer Costa Saroukos said that “does reflect some phasing,” and the company is still aiming for a mid single digit increase over the full year. Saroukos made the comment on what looks set to be his last quarterly results conference call as CFO of Takeda.  Milano Furuta, president of Takeda’s Japan pharma business unit, is preparing to take over as CFO in April. Saroukos is leaving because “after 20 years working abroad, I’m ready to move back to Australia to be closer to my family,” the outgoing CFO told investors.